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Screening identified 2-(3-((4,6-dioxo-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl)-2,5-dimethyl-1H-
pyrrol-1-yl)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile as an MDM2–p53 inhibitor (IC50 ¼
12.3 mM). MDM2–p53 and MDMX–p53 activity was seen for 5-((1-(4-chlorophenyl)-2,5-diphenyl-1H-pyrrol-
3-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (MDM2 IC50 ¼ 0.11 mM; MDMX IC50 ¼
4.2 mM) and 5-((1-(4-nitrophenyl)-2,5-diphenyl-1H-pyrrol-3-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-
trione (MDM2 IC50 ¼ 0.15 mM; MDMX IC50 ¼ 4.2 mM), and cellular activity consistent with p53 activation in
MDM2 amplified cells. Further SAR studies demonstrated the requirement for the triarylpyrrole moiety for
MDMX–p53 activity but not for MDM2–p53 inhibition.Introduction
The tumor suppressor protein p53 functions as a molecular
sensor in diverse signalling pathways resulting from cellular
stresses, such as DNA damage, oncogene activation and
possibly hypoxia.1 Abrogation of the function of the tumor
suppressor p53 is a key feature of the molecular pathology in
many cancers. Mutation of the TP53 gene occurs in approxi-
mately 50% of common adult sporadic cancers, resulting in
inactive protein.2,3 Alternatively, p53 may be silenced by the
overexpression of the regulatory proteins MDM2 or MDMX
(MDM4).4–6 MDM2 amplication has been reported to occur in
approximately 11% of all tumors and the paralogue MDMX has
been reported to be amplied in brain (11%), breast (5–40%),
and so tissue tumors (17%). Overexpression of MDMX has also
been observed in a wider range of tumor types, including uterus
(15%), testes (27%), melanoma (65%), stomach/small intestine
(43%), and lung (18%).6,7ute for Cancer Research and School of
ilding, Newcastle, NE1 7RU, UK. E-mail:
8591; Tel: +44 (0)191 222 6645
titute for Cancer Research, Newcastle
al School, Framlington Place, Newcastle,
k; Fax: +44 (0)191 4301; Tel: +44 (0)191
ESI) available: Experimental details for
r all compounds and intermediates.
ther details for the modeling. Table of
39/c3md00161j
Chemistry 2013The MDM2 and MDMX proteins regulate the activity of p53
with different and non-redundant mechanisms.8 In addition to
the MDM2 gene being a target for p53-dependent transcription,
MDM2 regulates p53 in an autoregulatory negative feedback loop
by binding to the p53 transactivation domain, and acting as an
E3-ligase for polyubiquitination of p53 to promote p53 degrada-
tion by the ubiquitin-mediated proteosomal pathway.9–12 MDMX
also inhibits p53 transcriptional activity, but does not act as an E3
ligase independently of MDM2, and its expression is not p53
dependent.13 Furthermore, MDMX–MDM2 heterodimers have
enhanced E3 ligase activity over MDM2 alone and may be an
important mechanism of p53 regulation.
The MDM2–p53 binding interaction is amenable to small-
molecule inhibition, as it consists of a relatively deep binding
groove on the surface of the MDM2 protein into which an
amphipathic helix of p53 binds.14 A number of potent MDM2–
p53 inhibitors have been reported based on diverse chemo-
types,15 such as the cis-imidazoline RG-7112 (IC50 ¼ 12 nM),16
spirooxindoles, e.g.MI-888 (IC50¼ 6.8 nM),17 and the substituted
piperidone AM-8553 (IC50 ¼ 2.2 nM),18 and have demonstrated
cellular activity consistent with inhibition of MDM2–p53 binding
and in vivo antitumor activity. However, these series lack signif-
icant potency against MDMX,19 and overexpression of MDMX
offers a possible mechanism of resistance to such MDM2–p53
inhibitors. For this reason compounds able to inhibit both
interactions have great signicance.20
To date, there have been few reports of small-molecule
MDMX inhibitors. The 5-oxo-pyrazolylidene SJ-172552 was
identied in an MDMX high-throughput uorescenceMed. Chem. Commun., 2013, 4, 1297–1304 | 1297
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View Article Onlinepolarisation assay and showed selective MDMX inhibition,
through a complex, irreversible mechanism.21,22 The 3-imida-
zolyl indole (1a) is a mixed MDM2–, MDMX–p53 inhibitor
(MDM2 IC50¼ 0.19 mM;MDMX IC50¼ 20 mM), and has provided
the rst X-ray crystal structure of MDMX bound to a small-
molecule ligand.19 A series of MDM2–p53 inhibitory pyrrolidone
derivatives, e.g. (2a, MDM2¼ 0.26 mM,MDMX¼ 2.7 mM; and 2b,
MDM2 ¼ 1.3 mM, MDMX ¼ 2.1 mM), also show modest MDMX
activity in addition to MDM2 inhibition.23 The indolyl hydan-
toins, e.g. RO-5963 (MDM2 ¼ 17 nM, MDMX ¼ 25 nM), are the
most potent MDM2–p53 and MDMX–p53 inhibitors reported to
date.24In this paper, we describe the discovery, structure–activity
relationships (SARs) and cellular activity of triarylpyrrole
compounds with promising inhibitory activity against both
MDM2–p53 andMDMX–p53. Comparison ofmolecularmodels of1298 | Med. Chem. Commun., 2013, 4, 1297–1304the triarylpyrroles with a small series of the related diarylpyrrole
MDM2–p53 inhibitors demonstrates key structural requirements
for mixed MDM2 and MDMX inhibition in this series.
Identication of MDM2–p53 inhibitors by screening
A pilot set of 800 structurally diverse compounds, obtained from
the Cancer Research UK screening collection was studied in an
MDM2–p53 ELISA protein–protein binding assay, at 5 and 20 mM
concentrations.25 Follow up IC50 determinations on active
compounds revealed pyrrole 3 as a hit, with an IC50 of 12.3 
1.5 mM against MDM2–p53, which also demonstrated dose-
dependent cellular activity by Western blotting for MDM2 andp53 induction. A series of 96 related analogues was purchased,
based on similarity searching and visual inspection, and
screened for MDM2 activity. Twelve compounds (4a–l) showed
promising MDM2–p53 inhibitory activity with IC50 values in theThis journal is ª The Royal Society of Chemistry 2013
Table 1 MDM2 structure–activity relationships for purchased pyrroles 4a–l
Compound R1 R2 R3 R4
MDM2 IC50
(nM)
4a 4-ClPh Me H H 720  100
4b 4-ClPh Me H Ph 3300  700
4c 4-ClPh Ph H H 120  20
4d 4-ClPh Ph H Ph 230  44
4e 4-ClPh Ph H 3-ClPh 163  17
4f 4-ClPh Ph 3,4-diMePh Ph 256  39
4g 4-ClPh Ph Me Me Insol.
4h 4-BrPh Me Ph Ph 199  16
4i 4-MePh Me H Ph 8400  900
4j 4-MePh Me H H 4700  200
4k 4-EtO2CPh Ph H H 700  20
Table 2 MDM2 and MDMX structure–activity relationships for triarylpyrroles 4c
and 4m–z
Compound R1 R2 X Y MDM2 IC50 (mM)
a MDMX IC50 (mM)
a
4c H H Cl S 0.11  0.03 4.2  1.2
4m H H Cl O 0.30  0.03 nd
4n H H Br O 0.18  0.07 nd
4o H H OMe O 1.9  0.3 13  7
4p H H t-Bu O 1.9  0.3 nd
4q H H CN O 4.7  1.9 7.0  3.0
4r H H CN S 0.20  0.07d 0.90  0.42
4s H H NO2 O 0.15  0.06 0.68  0.18
4t H H NO2 S 0.17  0.09d 0.63  0.12
4u Et Et Cl S 0.30  0.12c nd
4v Et Et Br O 0.89  0.04 74%b
4w Et Et Br S 0.26  0.05 nd
4x Me H Cl S 0.11  0.02d 28  23
4y Me H Br O 0.34  0.08 35  20
4z Me H Br S 0.073  0.002 nd
a n ¼ 3, from resynthesised material. b % inhibition at 50 mM. c n ¼ 6.
d n ¼ 4; nd ¼ not determined.
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View Article Online0.12–8.4 mM range (Table 1). Pyrroles bearing N2-aryl groups with
chloro-, bromo-, or ethoxylcarbonyl 4-substituents showed the
greatest potency. Pyrroles with 2,5-diphenyl substitution (4c, 4d)
were 5–10 fold more potent than the comparable 2,5-dimethyl
analogues (4a, 4b). Substitution on the thiobarbituric acidmoiety
had a modest negative effect on potency.
Synthesis and structure–activity relationships
In order to validate and further explore the SAR, a selection of
2,5-symmetrically substituted pyrroles 5 was prepared from
1,2-dibenzoylethane and the appropriate 4-substituted aniline,
using triuoroethanol (TFE) as solvent and triuoroacetic acid
(TFA) as catalyst under microwave heating (Scheme 1).26–29
The use of TFE-TFA with microwave heating is especially
advantageous over conventional procedures30 as it ensures
clean, homogeneous reactions that proceed in high yields.Scheme 1 Synthesis of substituted triarylpyrroles 4a–z. Reagents and conditions: (a
or AcOH, 120 C, 2 h.
This journal is ª The Royal Society of Chemistry 2013Formylation of the pyrroles under Vilsmeier–Haack conditions
proceeded smoothly with microwave heating to give 3-for-
mylpyrroles 6 in good yields. Condensation of aldehydes 6 with
the required barbituric or thiobarbituric acid was carried out in
ethanol at room temperature or in acetic acid at 120 C to give
the pyrrole barbiturates (4a–w). The use of mono-N-methyl
barbituric or thiobarbituric acid gave 4x–z as inseparable
mixtures of regioisomers.) TFA, TFE, MW, 150 C, 20 min; (b) POCl3 DMF, 0–70 C, MW, 1 h; (c) EtOH, rt, 12 h,
Med. Chem. Commun., 2013, 4, 1297–1304 | 1299
Scheme 2 Synthesis of substituted triarylpyrroles 7 and 7. Reagents and conditions: (a) toluene, piperidine, acetic acid, D; (b) NaBH4, EtOH.
Scheme 3 Synthesis of substituted triarylpyrroles 10a–f. Reagents and condi-
tions: (a) toluene, piperidine, acetic acid, D.
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View Article OnlineMDM2 inhibitory SARs for a series of analogues of 4c were
determined, and selected compounds were assayed for MDMX–
p53 inhibitory activity (Table 2). Unexpectedly, pyrrole 4c was
shown to be a low micromolar inhibitor of the MDMX–p53
interaction. Comparision of the MDM2 inhibitory activity of
matched pairs of thiobarbituric acid and barbituric acid deriva-
tives shows a 3–20 fold reduction in potency for the oxo-deriva-
tives (e.g. 4m and 4c, 4q and 4r, 4v and 4w, 4y and 4z), with the
exception of the 4-nitro derivatives 4s and 4t that were equi-
potent. The 4-N-aryl substitutents had a profound inuence on
potency for MDM2–p53. Thus, potency was conferred by chloro-
or bromo-substituents (4c, 4m, and 4n) or electron-withdrawing
groups e.g. nitro or cyano (4q–t). In contrast, larger or electron-
donating groups gave poor MDM2 inhibition, e.g. OCH3, t-Bu
(4o and 4p). The 4-aryl substituent also signicantly inuenced
activity against MDMX, with 4-nitro- (4s and 4t), 4-cyano- (4q and
4r), or 4-chloro- (4c)N-phenyl substituents conferring the greatest
inhibitory potency. The N,N-diethylbarbituric acid or thio-
barbituric acid derivatives (4u,v) were 3–4 fold less potent against
MDM2 compared with their unsubstituted analogues, whereas
the mono-N-methyl analogues (4x,y) were equipotent with their
parents. Similarly, N-alkyl substitution on the barbituric acid or
thiobarbituric acid moiety (4u–z) resulted in a signicant loss of
MDMX–p53 activity. In all cases reduced solubility was observed
for the N-alkyl derivatives.
A series of derivatives with alternative substituents to the
barbituric acid was prepared to explore the SAR for this moiety
for both MDM2 and MDMX inhibition. Compound 7 was
prepared by heating aldehyde 5b with Meldrum's acid 8 in
toluene with piperidine acetate as catalyst (Scheme 2). Reduc-
tion of 7 to 9 was achieved with sodium borohydride in ethanol.
The malonic acid derivatives 10a–e were prepared by conden-
sation of the required malonic acid, ester or amide with alde-
hyde 5a (Scheme 3). The reaction with malonic acid gave the
decarboxylated product 10f in addition to 10b.
The Meldrum's acid derivative 7 was >100-fold less potent
than 8c against MDM2–p53, whereas the reduced derivative 9
suffered a less signicant 20-fold reduction in potency (Table 3).
The acyclic derivatives 10a–f all lacked signicant MDMX–p53
activity, and showed reduced MDM2–p53 potency compared
with 4c. The dimethyl malonate derivative 10a was essentially1300 | Med. Chem. Commun., 2013, 4, 1297–1304inactive, whereas the malonic acid derivative 10b showed
modest activity against MDM2–p53. The malonamide derivative
10c showed similar activity to 10b, whereas the N-alkyl malo-
namide derivatives 10d and 10e showed a 3- and 6-fold loss of
potency against MDM2–p53. The monocarboxylic acid analogue
10f was only weakly active against MDM2–p53 and inactive
against MDMX–p53. These results suggest that binding to
MDM2 requires at least one H-bond donor in the 4-substituent.
A series of 2-alkyl-1,5-diarylpyrroles 11 was designed to probe
the SAR about the pyrrole for MDM2 and MDMX inhibition
(Table 4). Their synthesis required the preparation of 1,4-dike-
tones 12 via a Stetter reaction followed by cyclisation with the
appropriate aniline (Scheme 4).31 Formylation of pyrrole 13 gave
an inseparable mixture of isomers (14) that was reacted with
barbituric acid affording a mixture of 3- and 4-isomers 11 that
were only separable by HPLC (e.g. X ¼ Cl). The limited practi-
cality of this route prompted the search for a method capable of
yielding either regioisomer, as required. Thus, b-ketoesters 15,
prepared from Meldrum's acid 12, were subjected to a tandem
homologation/addition sequence mediated by the Furukawa
reagent,32 with oxidation of the intermediate providing the
a-ester 1,4-diketones 16 (Scheme 5).27 Regiospecic synthesis of
3-, and 4-substituted pyrroles was achieved by variation of the
R-groups on the b-ketoester and the aldehyde, providing both
regioisomeric a-ester 1,4-diketones 16 that were combined withThis journal is ª The Royal Society of Chemistry 2013
Table 3 MDM2 and MDMX structure–activity relationships for triarylpyrroles 7,
9, and 10a–f
Compound Structure R X Y
MDM2 IC50
(mM)a
MDMX IC50
(mM)a
7 A Me Br O 17  4b nd
9 B Me Br O 2.9  0.7b nd
10a C — Cl OMe >50 >50
10b C — Cl OH 2.9  0.2 >50
10c C — Cl NH2 2.5  0.2 30c
10d C — Cl NHMe 7.6  0.4 30c
10e C — Cl NH(CH2)2OH 15  3 42c
10f D — Cl OH 17  3 >50
a n ¼ 3. b n ¼ 5. c n ¼ 1; nd ¼ not determined.
Scheme 4 Synthesis of substituted diarylpyrrole 11a. Reagents and conditions:
(a) 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride, NEt3, RT; (b) TFA,
TFE, MW, 150 C, 20 min; (c) POCl3, DMF, 0–70 C MW, 1 h; (d) barbituric acid,
AcOH, 120 C.
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View Article Onlinethe required aniline. This is a versatile and efficient approach to
a variety of 1,2,3-trisubstituted pyrroles. The aldehydes 17 were
prepared from the esters 18 by DIBAL-H reduction to theTable 4 MDM2 and MDMX structure–activity relationships for diarylpyrroles
11a–g
Compound Isomer R1 X Y
MDM2 IC50
a
(mM)
MDMX IC50
b
(mM)
11a Mixture Me Cl O >1 nd
11b 3 t-Bu Br S 0.76  0.27c 963
11c 3 t-Bu Cl S 1.1  0.7c 1684
11d 4 CyPr Cl S 1.6  1.7 3486
11e 4 CyPr Br S 1.6  1.6 3428
11f 3 CyPr Cl S 2.1  2.7 4916
11g 3 CyPr Br S 2.2  2.7 5322
a n ¼ 3. b n ¼ 1. c n ¼ 4; nd ¼ not determined.
Scheme 5 Synthesis of substituted diarylpyrroles 11b–g. Reagents and condi-
tions: (a) pyridine, R1COCl, DCM, 0 C; (b) EtOH, toluene, reflux; (c) CH2I2, Et2Zn,
R2CHO DCM 0 C; (d) PCC, DCM, R.T.; (e) TFA, TFE, MW, 150 C or PTSA, toluene,
Dean–Stark; (f) DIBAL-H, DCM, 78 C; (g) TPAP, NMO, 4 A˚ MS, DCM, rt; (h) thi-
obarbituric acid, AcOH, 120 C-rt.
This journal is ª The Royal Society of Chemistry 2013corresponding alcohols 19 followed by oxidation.33 Condensa-
tion with thiobarbituric acid gave the desired non-symmetri-
cally substituted pyrroles 11b–g.
Substitution of the 2-phenyl residue with a methyl group
resulted in a greater than 3-fold loss of MDM2 inhibitory
potency for the mixture of regioisomers 11a (Table 4).
Replacement of the 5-phenyl with a tert-butyl group (11b,c) gave
a small loss of MDM2 inhibitory potency, independent of the
position of the thiobarbituric acid residue, but resulted in a
>200 fold loss of potency for MDMX. Similarly, the 2- or 5-
cyclopropyl derivatives retained modest MDM2 inhibitoryMed. Chem. Commun., 2013, 4, 1297–1304 | 1301
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View Article Onlineactivity, independent of the position of the thiobarbituric acid
residue, but were inactive against MDMX.Fig. 2 Modeled binding mode of 1,2-diarylpyrrole 11c (green) overlayed with
MDM2 (blue mesh) and MDMX (solid pink).MDM2 and MDMX modeling studies
Previously, we have demonstrated that docking ligands into the
MDM2 binding pocket can yield multiple low energy solu-
tions.34 For this reason, we opted to generate representative
binding modes for the pyrroles from the X-ray co-crystal struc-
tures of MDM2 and MDMX with structurally similar ligands, i.e.
imidazole derivatives (1a,b), by superposition and replacement
of the ligand.19 Pyrrole (4c) with mixed MDM2 and MDMX
potency, and two MDM2 selective pyrroles (11c and 11d) were
aligned in the ligands 1a in MDM2 (pdb: 3LBK) and 1b in
MDMX (pdb: 3LBJ), using the ligand builder function and the
CCP4 ‘cprodrg’ plugin within COOT.35,36 The high degree of
structural overlap between the original ligand and the modeled
compound in these models gives condence that the binding
modes are reasonable.
The binding modes for 4c in both MDM2 and MDMX (Fig. 1)
show good overlap with two of the aryl substituents of the
imidazole series (1a,b). In particular, the N-4-chlorophenyl ring
occupies the pocket normally lled by Trp23 of p53 for both
MDM2 andMDMX,14 overlaying the chloroindole ring of 1a or 1b.
The 5-phenyl ring of the pyrrole occupies the Phe19 pocket with
good overlap with the 1-phenyl ring of 1a or 1b. The remaining
phenyl ring is accommodated by the Leu26 pocket with a less well
dened overlap and different vector compared with the original
ligands. The thiobarbituric acid group projects away from the
protein surface into the space occupied by the carboxylic acid
residue of 1a and the amide group of 1b, suggesting that these
groups may act, in part, as a hydrophilic cap.37
The MDM2 binding mode model is consistent with the
observed SARs, as the Trp23 pocket of MDM2 shows a strong
preference for haloaromatic groups as seen in the X-ray struc-
tures of high-affinity ligands. The preference for haloaromatic
groups in the MDMX Trp23 binding-pocket is not as well
established as for MDM2 due to the smaller number of depos-
ited structures; however, the SARs in this series suggest that the
pocket is similar to that in MDM2.
The role of the barbituric acid or thiobarbituric acid group is
less well explained by the models. The positioning of the groups
in the models is consistent with that seen for the amide of 1aFig. 1 Modeled binding mode of 4c (green) overlayed with: (A) 1b (magenta) in
MDM2 (light blue); (B) 1a (purple) in MDMX (pink), binding pockets for p53
residues are indicated.
1302 | Med. Chem. Commun., 2013, 4, 1297–1304bound to MDMX and the acid group of 1b bound to MDM2, and
raises the possibility that water mediated H-bonding to the
protein backbone may be important for affinity.
The modelling of 11c into MDM2 and MDMX shows the N-4-
chlorophenyl group occupying the Trp23 pocket as seen for 4c
(Fig. 2). The t-butyl residue is positioned into the Phe19 binding
pocket, which is occupied by a number of alkyl substituents in
recent MDM2 X-ray structures, e.g. the MI-series (3LBL)19 and
the AM-8553 series (4ERE).18 The MDMX structure also places
the t-butyl group into the Phe19 pocket, but the 5-phenyl ring no
longer makes a good interaction with Leu26 pocket which
appears to be broader and shallower than for MDM2. This
observationmay explain the dramatic loss inMDMX potency for
this series, compared with the retention of MDM2 potency.
Interestingly, the model of 11d (ESI†), demonstrates the same
arrangement of substituents, regardless of the positioning of
the thiobarbituric acid moiety on the pyrrole ring.Cellular activity of pyrrole inhibitors
Growth inhibitory activity was determined for selected pyrroles in
a panel of cell lines with dened MDM2, MDMX and p53 status
(Table 5). The SJSA-1 osteosarcoma line has ampliedMDM2 and
wild-type p53, and is paired with the SN40R2 line (MDM2
amplied, p53 mutant), an SJSA-1 derived line that is resistant to
Nutlin-3a due to p53 mutation. For comparison, the MRK-NU-1
breast cancer cell line has amplied MDMX and wild-type p53.
Compounds showed growth inhibitory activity in the 2–10 mMTable 5 Growth inhibitory activity of pyrroles 4c, 4r, 4t, 4x in a panel of cell lines
with defined MDM2, MDMX and p53 statusa
Compound
GI50 (mM)
SJSA-1 SN40R2b MRK-NU-1
4cc 2.3  0.2 2.8  0.6 2.3  0.3
4rc 5.1  0.9 5.9  0.3 6.1  0.7
4tc 4.7  1.0 5.2  0.4 4.9  0.6
4xc 5.5  0.6 6.3  0.4 7.0  1.0
a n ¼ 3. b p53 null. c Resynthesised material.
This journal is ª The Royal Society of Chemistry 2013
Fig. 3 Cellular activity of 3, 4c and 4d for p53 pathway activation detected by western blotting in cell lines treated with increasing concentrations (mM) for 4 h: (A)
SJSA-1 cells; (B) A2780 cells; and (C) A2780CP70 cells.
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View Article Onlinerange without a strong correlation to either MDM2 or MDMX
inhibitory activity. Disappointingly, the compounds were equally
growth inhibitory in all cell lines regardless of their potency vs.
MDM2 or MDMX, and the MDM2 and MDMX status of the cell
line. Importantly, the p53 mutant SN40R2 line was equally
sensitive to the pyrroles 4c, 4r, 4t and 4x, in contrast to the 2–100
fold difference in activity reported for potent MDM2 inhibitors.
Cell lines with dened MDM2 and p53 status were treated
with increasing concentrations (0.1, 0.2 and 5 mM) of pyrroles 3,
4c and 4d to investigate the transcriptional activation of p53
and the subsequent induction of p53-dependent proteins by
Western blotting. In the SJSA-1 line (MDM2 amplied, p53wt)
induction of MDM2, p53 and p21 was clearly visible at 5 mM for
each compound (Fig. 3). In the A2780 line (p53wt) induction of
MDM2 and p21 is observed for 4c and 4d, but not for 3. Higher
levels of p53 obscured any induction in this case. In contrast, in
the A2780 CP70 line (p53 mutant) no induction of MDM2, p53,
and p21 was observed. In contrast to the growth inhibition data,
these results clearly demonstrate a p53-dependent cellular
response to the pyrroles.
Compounds with N-phenylpyrrole or alkylidene barbituric
acid groups have been identied as ‘frequent-hitters’ in HTS
campaigns.38 With this in mind, it is likely that, despite the
ability of these compounds to activate p53 dependent cellular
processes, the modest growth inhibition seen for this series is
the result of additional off-target activity.Conclusions
To date, the majority of potent MDM2–p53 inhibitors are highly
selective for MDM2 over MDMX, and there are very few pub-
lished inhibitors of MDM2 that retain signicant potency for
MDMX. The imidazole series, e.g. 1a, is reported to have weak
MDMX activity. The hydantoin derivative RO-5963 is reported to
be a potent dual MDM2 and MDMX inhibitor, but with an
unusual binding mode and cellular mechanism of action. We
have identied a series of 1,2,5-triarylpyrroles that display
MDM2–p53 and MDMX–p53 inhibitory activity in an cell-free
ELISA MDM2–p53 binding assay, and are able to activate p53-
dependent gene transcription in whole cells. Modeling studies
suggest a binding mode which is consistent with other reported
MDM2 inhibitors, and that offers insight into the structural
requirements for the design of compounds able to inhibit
both MDM2–p53 and MDMX–p53. However, the lack ofThis journal is ª The Royal Society of Chemistry 2013p53-dependent growth inhibitory activity and the poor physi-
cochemical properties for this series presents a substantial
challenge for their further development as drugs; however, they
represent interesting dual MDM2/MDMX ligands for both
structural and mechanistic studies.
AbbreviationsDCMMed. CDichloromethane
DIBAL-H Di-isopropylaluminium hydride
DIPEA Diisopropylethyl amine
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